MAIA Biotechnology Files 8-K

Ticker: MAIA · Form: 8-K · Filed: Feb 27, 2025 · CIK: 1878313

Sentiment: neutral

Topics: corporate-filing, 8-K, financial-update

TL;DR

MAIA Bio filed an 8-K on Feb 27, 2025, with corporate updates.

AI Summary

MAIA Biotechnology, Inc. filed an 8-K on February 27, 2025, reporting other events and financial statements. The filing details the company's corporate structure, including its state of incorporation (Delaware) and fiscal year end (December 31). The principal executive offices are located in Chicago, Illinois.

Why It Matters

This 8-K filing provides essential corporate and financial update information for MAIA Biotechnology, Inc., which is crucial for investors and stakeholders to understand the company's current status.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure and does not contain information that inherently increases risk.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

This 8-K filing serves as a Current Report by MAIA Biotechnology, Inc. to disclose other events and financial statements as of February 27, 2025.

When was the earliest event reported in this filing?

The earliest event reported in this filing occurred on February 27, 2025.

In which state is MAIA Biotechnology, Inc. incorporated?

MAIA Biotechnology, Inc. is incorporated in Delaware.

What is the address of MAIA Biotechnology, Inc.'s principal executive offices?

The principal executive offices of MAIA Biotechnology, Inc. are located at 444 West Lake Street, Suite 1700, Chicago, IL 60606.

What is the company's telephone number?

The company's telephone number, including area code, is (312) 416-8592.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on February 27, 2025 regarding MAIA Biotechnology, Inc. (MAIA).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing